Loxo Oncology (LOXO) Tops Q1 EPS by 60c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Loxo Oncology (LOXO) PT Raised to $145 at Stifel; All Eyes on LOXO-292 Data at ASCO
May 9, 2018 6:17 AM EDTStifel raised its price target on Loxo Oncology (NASDAQ: LOXO) to $145.00 (from $135.00) while maintaining a Buy rating.
Analyst Stephen Willey commented, "We continue to like LOXO shares into next months (June 2) presentation of P1 LOXO-292 data at the annual ASCO meeting as we... More
